Related Experiment Videos
[Calcium antagonists in treatment of ventricular tachycardia]
J Melichercik1, W Schöls, T Beyer
1Deutsches Herzzentrum Baden Klinik für Innere Medizin und Kardiologie, Lahr.
Insights
Calcium antagonists effectively treat specific ventricular tachycardias, offering a safer alternative to traditional antiarrhythmic drugs. This approach is beneficial for patients with certain arrhythmias, particularly young individuals without heart disease.
Area of Science:
- Cardiology
- Electrophysiology
Context:
- Class III antiarrhythmic agents are standard for ventricular tachycardias.
- Calcium antagonists (Class IV) are typically for supraventricular arrhythmias.
- Specific ventricular tachycardias may involve calcium-dependent mechanisms.
Purpose:
- To explore the efficacy of calcium antagonists in treating specific types of ventricular tachycardias.
- To identify patient populations and arrhythmia characteristics responsive to calcium antagonists.
Summary:
- Certain ventricular tachycardias, like verapamil-sensitive sustained left ventricular tachycardias, respond well to calcium antagonists.
- Exercise-induced and repetitive monomorphic ventricular tachycardias in young patients without structural heart disease show efficacy with calcium antagonists.
- Calcium antagonists provide an alternative to potentially harmful Class I and III antiarrhythmic agents.
Impact:
- Calcium antagonists offer an effective and safer therapeutic option for select ventricular tachycardias.
- This approach improves treatment outcomes for patients, especially young individuals with specific arrhythmia types.
- Highlights the importance of targeted diagnosis for optimal arrhythmia management.
Abstract:
Of the traditional antiarrhythmic agents administered in the treatment of ventricular tachycardias, those belonging to Class III are most commonly used. However, some ventricular tachycardias displaying special clinical, electrocardiographic and/or electrophysiologic characteristics have been successfully treated with calcium antagonists. Otherwise, Class IV antiarrhythmic agents are primarily used in the treatment of supraventricular tachyarrhythmias. It is reasonable to suspect that calcium-dependent phenomena underlie ventricular tachyarrhythmias in a number of patients. Verapamil-sensitive sustained left ventricular tachycardias represent a typical example. Sufficient response to calcium antagonists has also been demonstrated for exercise-induced ventricular tachycardias and repetitive monomorphic ventricular tachycardias. Characteristically, these arrhythmias occur in young patients with no structural heart disease. The long-term prognosis of these patients is in fact very good, but because of intrusive symptoms, pharmacological or nonpharmacological (radiofrequency ablation) treatment is often indicated. Through correct diagnosis and implementation of a short- and long-term therapy with calcium antagonists, and excellent alternative to the potentially harmful therapy with Class I and Class III antiarrhythmic agents can be offered.